The FDA has approved inotuzumab ozogamicin for the treatment of pediatric patients aged one year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.
[OncLive]
Home Newsletters Hematopoiesis News FDA Approves Inotuzumab Ozogamicin for Pediatric CD22+ B-Cell Precursor Acute Lymphoblastic Leukemia
